RxDoctor Payments Data

John Absher, MD

Neurology · Greenville, SCNPI 1417949751

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $23,213 of the $30,222 with a category attached, or 76.8%. Eisai Inc. accounts for 93.8% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2024 at $13,487 and has fallen 60.1% since, to $5,384 in 2025. Among neurology clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$30,222in general payments, 2019–2025

Across 163 payments — averaging $185.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$28K
  • AbbVie$208
  • Supernus Pharmaceuticals, Inc.$187
  • AstraZeneca$151
  • Novartis$137
  • Biogen$135
  • plus $1K from 22 others

What the payments were for

  • Consulting fees$3,82313%
  • Speaking & faculty fees$23,21377%
  • Travel & lodging$7913%
  • Food & beverage$2,2768%
  • Education$1190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,222 in reported general payments places this provider in the 90th percentile of 270 neurology providers in South Carolina.

See all neurology providers in South Carolina

Medicare billing

Part B allowed, 2024
$87,395
Medicare patients
425
Services billed
754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Memantine Hcl105$7,622
Clobazam12$3,034
Rivastigmine13$1,578
Donepezil Hcl96$1,357
Lacosamide13$1,089
RivastigmineRivastigmine Tartrate24$983
Gabapentin28$401
Mirtazapine23$382
Quetiapine Fumarate ErQuetiapine Fumarate11$346
Levetiracetam16$328
Carbidopa-LevodopaCarbidopa/Levodopa13$323
Escitalopram Oxalate31$254
Risperidone20$170
Trazodone Hcl36$153
Propranolol Hcl ErPropranolol Hcl12$138

Paid to pharmacies, not to this prescriber.

Other neurology in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →